Immunic Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Immunic ha un patrimonio netto totale di $41.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $64.8M e $23.5M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$59.07m
Patrimonio netto	US$41.22m
Totale passività	US$23.54m
Totale attività	US$64.76m

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 25

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Recent updates

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 25

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Immunic stock gains on $60M oversubscribed PIPE financing

Oct 10

Immunic GAAP EPS of -$0.72 in-line

Aug 04

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Jul 27

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Apr 13

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Dec 24

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Aug 13

We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

May 10

Immunic EPS misses by $0.95

May 06

Immunic EPS misses by $0.07

Nov 05

Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19

Nov 02

Immunic (IMUX) Investor Presentation - Slideshow

Oct 31

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $63.3M ) di IMUX superano le sue passività a breve termine ( $23.4M ).

Passività a lungo termine: Le attività a breve termine di IMUX ( $63.3M ) superano le sue passività a lungo termine ( $186.0K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: IMUX è esente da debiti.

Riduzione del debito: IMUX non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: IMUX ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: IMUX ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 22.3 % ogni anno

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/01/10 00:53
Prezzo dell'azione a fine giornata	2025/01/10 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Immunic, Inc. è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
George Farmer	BMO Capital Markets Equity Research
William Wood	B. Riley Securities, Inc.
Tyler Bussian	Brookline Capital Markets

Immunic Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Recent updates

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors